miR-21, Mediator, and Potential Therapeutic Target in the Cardiorenal Syndrome
Oligonucleotide-based therapies are currently gaining attention as a new treatment option for relatively rare as well as common diseases such as cardiovascular disease. With the remarkable progression of new sequencing technologies, a further step towards personalized precision medicine to target a...
| Main Authors: | , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Frontiers Media S.A.
2020-05-01
|
| Series: | Frontiers in Pharmacology |
| Subjects: | |
| Online Access: | https://www.frontiersin.org/article/10.3389/fphar.2020.00726/full |
| _version_ | 1819267588611375104 |
|---|---|
| author | Cheng-Kai Huang Christian Bär Christian Bär Thomas Thum Thomas Thum |
| author_facet | Cheng-Kai Huang Christian Bär Christian Bär Thomas Thum Thomas Thum |
| author_sort | Cheng-Kai Huang |
| collection | DOAJ |
| description | Oligonucleotide-based therapies are currently gaining attention as a new treatment option for relatively rare as well as common diseases such as cardiovascular disease. With the remarkable progression of new sequencing technologies, a further step towards personalized precision medicine to target a disease at a molecular level was taken. Such therapies may employ antisense oligonucleotides to modulate the expression of both protein coding and non-coding RNAs, such as microRNAs. The cardiorenal syndrome (CRS) is a complex and severe clinical condition where heart and renal dysfunction mutually affect one another. The underlying mechanisms remain largely unknown and current treatments of CRS are mainly supportive therapies which slow down the progression of the disease, but hardly improve the condition. The small non-coding RNA, microRNA-21 (miR-21), is dysregulated in various heart and kidney diseases and has been repeatedly suggested as therapeutic target for the treatment of CRS. Impressive preclinical results have been achieved by an antisense oligonucleotide-based therapy to effectively block the pro-fibrotic traits of miR-21. Since microRNA-mediated pathways are generally very well-conserved, there is considerable commercial interest with regards to clinical translation. In this review, we will summarize the role of miR-21 within the heart–kidney axis and discuss the advantages and pitfalls of miR-21 targeting therapeutic strategies in CRS. |
| first_indexed | 2024-12-23T21:19:33Z |
| format | Article |
| id | doaj.art-53afdb73eeb3443abe1d102e3e0190a1 |
| institution | Directory Open Access Journal |
| issn | 1663-9812 |
| language | English |
| last_indexed | 2024-12-23T21:19:33Z |
| publishDate | 2020-05-01 |
| publisher | Frontiers Media S.A. |
| record_format | Article |
| series | Frontiers in Pharmacology |
| spelling | doaj.art-53afdb73eeb3443abe1d102e3e0190a12022-12-21T17:30:48ZengFrontiers Media S.A.Frontiers in Pharmacology1663-98122020-05-011110.3389/fphar.2020.00726442028miR-21, Mediator, and Potential Therapeutic Target in the Cardiorenal SyndromeCheng-Kai Huang0Christian Bär1Christian Bär2Thomas Thum3Thomas Thum4Institute of Molecular and Translational Therapeutic Strategies, Hannover Medical School, Hannover, GermanyInstitute of Molecular and Translational Therapeutic Strategies, Hannover Medical School, Hannover, GermanyREBIRTH Center for Translational Regenerative Medicine, Hannover Medical School, Hannover, GermanyInstitute of Molecular and Translational Therapeutic Strategies, Hannover Medical School, Hannover, GermanyREBIRTH Center for Translational Regenerative Medicine, Hannover Medical School, Hannover, GermanyOligonucleotide-based therapies are currently gaining attention as a new treatment option for relatively rare as well as common diseases such as cardiovascular disease. With the remarkable progression of new sequencing technologies, a further step towards personalized precision medicine to target a disease at a molecular level was taken. Such therapies may employ antisense oligonucleotides to modulate the expression of both protein coding and non-coding RNAs, such as microRNAs. The cardiorenal syndrome (CRS) is a complex and severe clinical condition where heart and renal dysfunction mutually affect one another. The underlying mechanisms remain largely unknown and current treatments of CRS are mainly supportive therapies which slow down the progression of the disease, but hardly improve the condition. The small non-coding RNA, microRNA-21 (miR-21), is dysregulated in various heart and kidney diseases and has been repeatedly suggested as therapeutic target for the treatment of CRS. Impressive preclinical results have been achieved by an antisense oligonucleotide-based therapy to effectively block the pro-fibrotic traits of miR-21. Since microRNA-mediated pathways are generally very well-conserved, there is considerable commercial interest with regards to clinical translation. In this review, we will summarize the role of miR-21 within the heart–kidney axis and discuss the advantages and pitfalls of miR-21 targeting therapeutic strategies in CRS.https://www.frontiersin.org/article/10.3389/fphar.2020.00726/fullmicroRNAnon-coding RNA (ncRNA)antisense-oligonucleotidescardiorenal syndrome (CRS)miR-21miR-21 inhibitor |
| spellingShingle | Cheng-Kai Huang Christian Bär Christian Bär Thomas Thum Thomas Thum miR-21, Mediator, and Potential Therapeutic Target in the Cardiorenal Syndrome Frontiers in Pharmacology microRNA non-coding RNA (ncRNA) antisense-oligonucleotides cardiorenal syndrome (CRS) miR-21 miR-21 inhibitor |
| title | miR-21, Mediator, and Potential Therapeutic Target in the Cardiorenal Syndrome |
| title_full | miR-21, Mediator, and Potential Therapeutic Target in the Cardiorenal Syndrome |
| title_fullStr | miR-21, Mediator, and Potential Therapeutic Target in the Cardiorenal Syndrome |
| title_full_unstemmed | miR-21, Mediator, and Potential Therapeutic Target in the Cardiorenal Syndrome |
| title_short | miR-21, Mediator, and Potential Therapeutic Target in the Cardiorenal Syndrome |
| title_sort | mir 21 mediator and potential therapeutic target in the cardiorenal syndrome |
| topic | microRNA non-coding RNA (ncRNA) antisense-oligonucleotides cardiorenal syndrome (CRS) miR-21 miR-21 inhibitor |
| url | https://www.frontiersin.org/article/10.3389/fphar.2020.00726/full |
| work_keys_str_mv | AT chengkaihuang mir21mediatorandpotentialtherapeutictargetinthecardiorenalsyndrome AT christianbar mir21mediatorandpotentialtherapeutictargetinthecardiorenalsyndrome AT christianbar mir21mediatorandpotentialtherapeutictargetinthecardiorenalsyndrome AT thomasthum mir21mediatorandpotentialtherapeutictargetinthecardiorenalsyndrome AT thomasthum mir21mediatorandpotentialtherapeutictargetinthecardiorenalsyndrome |